Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
The UK Department of Health and Social Care added Co-codamol (30mg/500mg, all formulations) to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 28 January 2026. DHSC had issued a medicine supply warning for co-codamol 30mg/500mg on 12 January 2026, projecting limited supply into at least early June 2026. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.
The UK Department of Health and Social Care added Aspirin (all strengths and forms) and Ifosfamide (1g/2g powder for solution for injection vials, a chemotherapy agent) to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 17 January 2026. Pharmacy trade press reported the addition followed manufacturing delays and raw- ingredient shortages that had left UK pharmacies short of aspirin stock. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.